in a news release, the drug's manufacturer, amgen, said the list price will be 5 a month or ,900 annually. costs to patients may vary depending on insurance.
.
"we are glad our concerns have been addressed by the coroner's office but the western trust has a lot to answer for.
. may 16, 2018
.
following close on aimovig's heels are three other drugs that target cgrp: fremanezumab, galcanezumab, and eptinezumab (which is given by iv).
.
may 16, 2018
.